Valuation: Silence Therapeutics plc

Market Cap 638M 864M 746M 702M 1.2B 82.78B 1.22B 8.24B 3.23B 41.4B 3.24B 3.17B 138B P/E 2026 *
-20.9x
P/E 2027 * -17.3x
Enterprise Value 505M 684M 591M 556M 950M 65.52B 964M 6.52B 2.55B 32.77B 2.57B 2.51B 109B EV / Sales 2026 *
1,555x
EV / Sales 2027 * 618x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Silence Therapeutics plc

1 day-1.74%
1 week-4.21%
Current month+34.41%
1 month+34.29%
3 months+126.32%
6 months+190.12%
Current year+131.91%
1 week 13.36
Extreme 13.36
14.41
1 month 10.16
Extreme 10.16
17.58
Current year 4.19
Extreme 4.19
17.58
1 year 4.19
Extreme 4.19
17.58
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 2025-11-30
Director of Finance/CFO 54 2022-01-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 63 2018-06-20
Chairman 72 2003-12-31
Director/Board Member 65 2025-05-04
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Sell 865,112 0.6105%
1/2/26 Free

Chief Financial Officer

375,000 0.2646%
1/2/26 Free

Director

90,000 0.0635%
Change 5-day change 1-year change 3-year change Capi.($)
-1.74%-4.21%+155.43%+101.72% 864M
-0.11%-1.67%+1.80%+19.90% 48.84B
+1.89%+5.08%+492.59%+629.24% 45.44B
+1.83%+2.75%+15.61%+91.22% 41.22B
-0.50%-1.56%+24.67%+12.17% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+0.59%-2.25% - - 16.25B
-1.14%-2.51%+27.52%+136.42% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-2.60%-1.00%+77.85%+40.37% 13.68B
Average -0.50%-1.85%+90.69%+124.03% 26.94B
Weighted average by Cap. -0.02%-1.09%+104.16%+153.93%

Financials

2026 *2027 *
Net sales 325K 440K 380K 357K 611K 42.13M 620K 4.19M 1.64M 21.07M 1.65M 1.61M 70.18M 751K 1.02M 878K 826K 1.41M 97.37M 1.43M 9.69M 3.8M 48.7M 3.82M 3.73M 162M
Net income -41.45M -56.12M -48.47M -45.61M -77.96M -5.38B -79.1M -535M -210M -2.69B -211M -206M -8.96B -66.28M -89.74M -77.51M -72.93M -125M -8.6B -126M -855M -335M -4.3B -337M -330M -14.32B
Net Debt -133M -180M -156M -146M -250M -17.27B -254M -1.72B -673M -8.64B -677M -662M -28.76B -174M -236M -204M -191M -327M -22.58B -332M -2.25B -880M -11.29B -885M -866M -37.61B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
26-08-18 US$14.10 -1.74% 1,487,569
26-08-17 US$14.35 +4.59% 1,002,276
26-08-14 US$13.72 -1.79% 824,056
26-08-13 US$13.97 +2.87% 2,814,361
26-08-12 US$13.58 -7.74% 5,443,587
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.10USD
Average target price
33.00USD
Spread / Average Target
+134.04%

Quarterly revenue - Rate of surprise